GlassScriptPhysician profile
John Barnard Adams
NPI 1013081678
$14,686.04
in general payments reported to CMS, 2019-2025
39 companies · $423 in 2025
The $423 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,745 · 2020: $3,023 · 2021: $2,788 · 2022: $2,574 · 2023: $1,426 · 2024: $706 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,755 · Travel and Lodging: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,755.30 |
| Travel and Lodging | $800.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $10,832.39 | 2019-2025 | Rezum Generator, Ams 700 |
| Procept Biorobotics Corporation | $1,191.45 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Arthrex, INC. | $323.42 | 2023 | |
| Teleflex LLC | $317.50 | 2021-2025 | Urolift |
| Olympus America INC. | $227.96 | 2024-2025 | Itind System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.12 | 2019-2020 | |
| Calyxo, INC. | $144.42 | 2025 | Cvac Aspiration System |
| Astellas Pharma US INC | $123.55 | 2019-2022 | |
| Allergan, INC. | $115.40 | 2019-2021 | |
| Coloplast Corp | $99.49 | 2019-2023 | Speedicath |
| Myovant Sciences INC. | $97.37 | 2021-2022 | |
| Avanos Medical | $95.31 | 2023 | On-Q* Pump and Accessories |
| Dentsply Ih INC. | $74.59 | 2021-2022 | |
| Neotract INC. | $73.57 | 2019 | |
| Abbvie INC. | $67.90 | 2019-2023 | Botox |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $65.49 | 2022 | |
| Merck Sharp & Dohme LLC | $53.20 | 2021-2022 | |
| Therapeuticsmd, INC. | $50.57 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $49.65 | 2021-2022 | |
| Urogen Pharma, INC. | $45.15 | 2022-2023 | Jelmyto |
| Bayer Healthcare Pharmaceuticals INC. | $43.20 | 2019-2020 | |
| Abbott Laboratories | $42.06 | 2019 | |
| Abc Home Medical Supply, INC. | $37.38 | 2024 | |
| Convatec INC. | $34.67 | 2020-2021 | |
| Pfizer INC. | $29.69 | 2019 | |
| Urovant Sciences INC | $27.74 | 2022 | |
| Janssen Biotech, INC. | $26.19 | 2025 | Erleada |
| Verity Pharmaceuticals INC. | $24.87 | 2025 | Trelstar |
| Tolmar Pharmaceuticals, INC. | $24.85 | 2019 | |
| Sumitomo Pharma America, INC. | $23.24 | 2023 | Gemtesa |
| Myriad Genetic Laboratories, INC. | $17.80 | 2022 | |
| Ambu INC. | $17.21 | 2021 | |
| Cook Medical LLC | $17.06 | 2020 | |
| Ethicon US, LLC | $16.69 | 2021 | |
| Endo Pharmaceuticals INC. | $16.55 | 2020 | |
| Ferring Pharmaceuticals INC. | $16.19 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $15.37 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $12.99 | 2019 | |
| Sagent Pharmaceuticals | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.